期刊
EPILEPSY RESEARCH
卷 127, 期 -, 页码 311-316出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2016.09.019
关键词
miR-106b; miR-146a; Epilepsy; Circulating miRNA; Biomarker
资金
- HeiLongJiang Province Department of Education Project [12531734]
- Mudanjiang City Science and Technology Plan Projects [z2014s014]
Background: Epilepsy is a chronic neurological disorder characterized by recurring seizures. Although scalp electroencephalograms (EEG) and neuroimaging have been used in clinical diagnosis of epilepsy, the more economical, rapid and non-invasive biomarker is still desirable, contributing to the accurate clinical diagnosis and facilitating the appropriate treatment. Methods: The expression of four epilepsy-associated miRNAs (miR-106b, miR-146a, miR-194-5p and miR-301a) was measured by quantitative RT-PCR in the serum of 90 epilepsy patients and control populations. Results: It was found that the serum miR-106b, miR-146a and miR-301a were significantly increased but serum miR-194-5p was significantly decreased in epilepsy patients compared with healthy control populations. In addition, serum miR-106b (r = 0.6412) and miR-146a (r = 0.5896) were correlated with NHS3 score in epilepsy patients. Furthermore, the ROC result of serum miR-106b for prediction of epilepsy was 0.786, higher than those of serum miR-146a (AUC = 0.774), miR-194 (AUC = 0.686) or miR-310a (AUC = 0.696). The combination of serum miR-106b and miR-146a gained a better sensitivity/specificityfor prediction of epilepsy (AUC = 0.887). Conclusion: Our preliminary findings indicate that upregulated serum miR-106b and miR-146a might be a potential biomarker for epilepsy evaluation. (C) 2016 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据